VARIANTES IL-2 MODIFIÉES D'ACTIVATION SÉLECTIVE DE LYMPHOCYTES T RÉGULATEURS POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES

摘要

The invention described herein is a novel IL-2 protein with selective agonist activity for Regulatory T cells and with an additional amino acid substitution that enable chemical conjugation with Polyethyene Glycol (PEG) that increase circulating half- life compared to the IL-2 selective agonist alone. A preferred IL-2 selective agonist variant is IL2/N88R/C125S/D109C.